Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BioXcel Therapeutics, Inc. Director's Dealing 2024

Nov 25, 2024

34564_dirs_2024-11-25_5bfd79d1-e285-4914-a68e-2b2614073834.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: BioXcel Therapeutics, Inc. (BTAI)
CIK: 0001720893
Period of Report: 2024-11-21

Reporting Person: MACK DAVID J. (Director)